rationale-306: tislelizumab and chemotherapy in escc
Published 1 year ago • 89 plays • Length 4:03Download video MP4
Download video MP3
Similar videos
-
3:09
rationale-306: asian subgroup of 1l tislelizumab chemo vs chemo alone for esophageal scc
-
2:16
distinguish: dkn-01 with tislelizumab and chemotherapy in gc/gejc
-
0:27
rationale-305: tislelizumab chemo vs placebo chemo in advanced gc/gejc
-
3:14
rationale-301: elderly subgroup analysis of tislelizumab in hcc
-
2:01
qol analyses from rationale-301 of tislelizumab vs sorafenib in hcc
-
2:58
tislelizumab in patients with unresectable hcc demonstrates durable responses
-
7:47
tislelizumab in oesophageal cancer after systemic therapy
-
3:12
tislelizumab os benefit vs sorafenib as first line treatment for unresectable hepatocellular car...
-
1:15
results of phase ii study of tislelizumab in r/r nk/t-cell neoplasms
-
1:45
association of pathologic complete response following neoadjuvant chemotherapy with longterm sur...
-
1:37
dr. choueiri on synergy between immunotherapy and vegf inhibitors in rcc
-
4:32
novel advances in the management of gc/gejc
-
4:12
eribulin in recurrent metastatic er breast cancer
-
4:45
what is lymphodepleting chemotherapy?
-
16:47
what is needed and what is the role of biosimilars?
-
0:53
dr. shah discusses challenges with immunotherapy in esophageal cancer
-
0:30
options for esophageal cancer patients | cedars-sinai
-
3:01
esophageal cancer by staci e. beamer, md | preview
-
1:44
unmet needs in chemoradiotherapy for esophageal cancer